Release and swelling studies of an innovative antidiabetic-bile acid microencapsulated formulation, as a novel targeted therapy for diabetes treatment

QR Code

Release and swelling studies of an innovative antidiabetic-bile acid microencapsulated formulation, as a novel targeted therapy for diabetes treatment

In previous studies carried out in our laboratory, a bile acid formulation exerted a hypoglycaemic effect in a rat model of type 1 diabetes (T1D). When the antidiabetic drug gliclazide was added to the bile acid, it augmented the hypoglycaemic effect. In a recent study, we designed a new formulation...

Full description

Bibliographic Details
Main Authors:	Mooranian, Armin, Negrulj, Rebecca, Al-Sallami, H., Fang, Zhongxiang, Mikov, M., Golocorbin-Kon, S., Fakhoury, M., Arfuso, Frank, Al-Salami, Hani
Format:	Journal Article
Published:	Informa Healthcare 2015
Online Access:	http://hdl.handle.net/20.500.11937/43970

Similar Items

Release and swelling studies of an innovative antidiabetic-bile acid microencapsulated formulation, as a novel targeted therapy for diabetes treatment (vol 32, pg 151, 2014)
by: Mooranian, A., et al.
Published: (2015)

Novel artificial cell microencapsulation of a complex gliclazide-deoxycholic bile acid formulation: A Characterization Study
by: Mooranian, Armin, et al.
Published: (2014)

Swelling, mechanical strength, and release properties of probucol microcapsules with and without a bile acid, and their potential oral delivery in diabetes
by: Negrulj, R., et al.
Published: (2015)

Microencapsulation as a novel delivery method for the potential antidiabetic drug, Probucol
by: Mooranian, Armin, et al.
Published: (2014)

Novel chenodeoxycholic acid-sodium alginate matrix in the microencapsulation of the potential antidiabetic drug, probucol. An in vitro study
by: Mooranian, A., et al.
Published: (2015)

Characterization of a novel bile acid-based delivery platform for microencapsulated pancreatic ß-cells.
by: Mooranian, Armin, et al.
Published: (2014)

An advanced microencapsulated system: a platform for optimized oral delivery of antidiabetic drug-bile acid formulations
by: Mooranian, A., et al.
Published: (2015)

Viability and topographical analysis of microencapsulated ß-cells exposed to a biotransformed tertiary bile acid: An ex vivo study
by: Mooranian, Armin, et al.
Published: (2016)

Potentials and Limitations of Bile Acids in Type 2 Diabetes Mellitus: Applications of Microencapsulation as a Novel Oral Delivery System
by: Negrulj, Rebecca, et al.
Published: (2013)

Probucol Release from Novel Multicompartmental Microcapsules for the Oral Targeted Delivery in Type 2 Diabetes
by: Mooranian, Armin, et al.
Published: (2014)

Stability and Release Kinetics of an Advanced Gliclazide-Cholic Acid Formulation: The Use of Artificial-Cell Microencapsulation in Slow Release Targeted Oral Delivery of Antidiabetics
by: Mooranian, Armin, et al.
Published: (2014)

An optimized probucol microencapsulated formulation integrating a secondary bile acid (deoxycholic acid) as a permeation enhancer
by: Mooranian, Armin, et al.
Published: (2014)

Advanced bile acid-based multi-compartmental microencapsulated pancreatic ß-cells integrating a polyelectrolyte-bile acid formulation, for diabetes treatment.
by: Mooranian, A., et al.
Published: (2014)

The effect of a tertiary bile acid, taurocholic acid, on the morphology and physical characteristics of microencapsulated probucol: potential applications in diabetes: a characterization study
by: Mooranian, A., et al.
Published: (2015)

Pharmacological effects of nanoencapsulation of human-based dosing of probucol on ratio of secondary to primary bile acids in gut, during induction and progression of type 1 diabetes
by: Mooranian, Armin, et al.
Published: (2018)

The impact of allylamine-bile acid combinations on cell delivery microcapsules in diabetes
by: Mooranian, Armin, et al.
Published: (2016)

Novel artificial cell microencapsulation of probucol and bile acids in diabetes mellitus
by: Mooranian, Armin
Published: (2018)

Diabetes development increased concentrations of the conjugated bile acid, taurocholic acid in serum, while treatment with microencapsulated-taurocholic acid exerted no hypoglycaemic effects
by: Mathavan, S., et al.
Published: (2017)

Eudragit®-based microcapsules of probucol with a gut-bacterial processed secondary bile acid
by: Mooranian, A., et al.
Published: (2018)

High-Loading Dose of Microencapsulated Gliclazide Formulation Exerted a Hypoglycaemic Effect on Type 1 Diabetic Rats and Incorporation of a Primary Deconjugated Bile Acid, Diminished the Hypoglycaemic Antidiabetic Effect
by: Golocorbin-Kon, S., et al.
Published: (2017)

Bile acids and their derivatives as potential modifiers of drug release and pharmacokinetic profiles
by: Pavlovic, N., et al.
Published: (2018)

Novel multicompartmental bile acid-based microcapsules for pancreatic β-cell transplantation
by: Mooranian, A., et al.
Published: (2015)

Flow vibration-doubled concentric system coupled with low ratio amine to produce bile acid-macrocapsules of ß-cells
by: Mooranian, Armin, et al.
Published: (2016)

Morphological, Stability, and Hypoglycemic Effects of New Gliclazide-Bile Acid Microcapsules for Type 1 Diabetes Treatment: the Microencapsulation of Anti-diabetics Using a Microcapsule-Stabilizing Bile Acid
by: Mathavan, S., et al.
Published: (2018)

NOVEL MULTICOMPARTMENTAL BILE ACID-BASED MICROCAPSULES FOR PANCREATIC beta-CELL TRANSPLANTATION
by: Mooranian, A., et al.
Published: (2015)

Inflammatory bowel disease: clinical aspects and treatments
by: Fakhoury, M., et al.
Published: (2014)

Application of bile acids in drug formulation and delivery
by: Stojancevic, M., et al.
Published: (2014)

Probiotics decreased the bioavailability of the bile acid analog, monoketocholic acid, when coadministered with gliclazide, in healthy but not diabetic rats
by: Al-Salami, Hani, et al.
Published: (2012)

Pharmacological Applications of Bile Acids and Their Derivatives in the Treatment of Metabolic Syndrome
by: Danic, M., et al.
Published: (2018)

Primary Bile Acid Chenodeoxycholic Acid-Based Microcapsules to Examine ß-cell Survival and the Inflammatory Response
by: Mooranian, A., et al.
Published: (2016)

New biotechnological microencapsulating methodology utilizing individualized gradient-screened jet laminar flow techniques for pancreatic ß-cell delivery: bile acids support cell energy-generating mechanisms
by: Mooranian, A., et al.
Published: (2017)

Long-Term Supplementation of Microencapsulated ursodeoxycholic Acid Prevents Hypertension in a Mouse Model of Insulin Resistance:
by: Al-Salami, Hani, et al.
Published: (2016)

The roles of bile acids and applications of microencapsulation technology in treating Type 1 diabetes mellitus
by: Woodhams, L., et al.
Published: (2017)

Alginate-deoxycholic Acid Interaction and Its Impact on Pancreatic ?-Cells and Insulin Secretion and Potential Treatment of Type 1 Diabetes
by: Mooranian, Armin, et al.
Published: (2016)

Potential Applications of Gliclazide in Treating Type 1 Diabetes Mellitus: Formulation with Bile Acids and Probiotics
by: Mikov, M., et al.
Published: (2017)

The incorporation of water-soluble gel matrix into bile acid-based microcapsules for the delivery of viable ß-cells of the pancreas, in diabetes treatment: biocompatibility and functionality studies.
by: Mooranian, A., et al.
Published: (2015)

Electrokinetic potential-stabilization by bile acid-microencapsulating formulation of pancreatic ß-cells cultured in high ratio poly-L-ornithine-gel hydrogel colloidal dispersion: applications in cell-biomaterials, tissue engineering and biotechnological applications
by: Mooranian, A., et al.
Published: (2017)

An in vivo pharmacological study: Variation in tissue-accumulation for the drug probucol as the result of targeted microtechnology and matrix-acrylic acid optimization and stabilization techniques
by: Mooranian, Armin, et al.
Published: (2019)

Novel nano-encapsulation of probucol in microgels: scanning electron micrograph characterizations, buoyancy profiling, and antioxidant assay analyses
by: Mooranian, A., et al.
Published: (2018)

The biological effects of the hypolipidaemic drug probucol microcapsules fed daily for 4 weeks, to an insulin-resistant mouse model: potential hypoglycaemic and anti-inflammatory effects
by: Mooranian, Armin, et al.
Published: (2018)

Cannot write session to /tmp/vufind_sessions/sess_fldbgvrfi1de596mveouimjpgq